StockUnited StatesNasdaqGS

ARQT

Arcutis Biotherapeutics, Inc.

Healthcare · Biotechnology

31.20USD

-1.0000 (-3.11%)

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out

Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
A take fades: it counts half as much after 7 days and drops out after 30.
Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
Your own take is private: only the totals are shown, and never who said what.

Description Historical Financials Relative Value Research News Community Room OptionsPrice Chart ↗Fundamental Chart ↗

In $M except per-share	Q2 FY26	Q1 FY26	Q4 FY25*	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24*	Q3 FY24
Revenue	130	105	130	99	82	66	71	45
Cost of Revenue	11	10	12	9	7	9	7	6
Gross Profit	119	96	118	91	74	57	64	39
Operating Income	16	-9	18	9	-15	-25	-8	-39
Net Income	15	-11	17	7	-16	-25	-11	-42
EPS (Diluted)	$0.11	-$0.09	$0.13	$0.06	-$0.13	-$0.20	-$0.08	-$0.33

* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)

Fetching financial statements from SEC filings…